Company: SCLXW
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047800
Chunk: 186

Company: Scilex Holding Co
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 186
---
 market price for our Common Stock could negatively affect our ability to issue new equity to fund our activities.

If our operations and performance do not meet the expectations of investors or securities analysts, the market price of our securities may decline. 

Any of the factors listed below could have a negative impact on your investment in our securities, and our securities may trade at prices significantly below the price you paid for them. In such circumstances, the trading price of our securities may not recover and may experience a further decline. 

Factors affecting the trading price of our securities may include: 

•our ability to commercialize ZTlido, GLOPERBA, ELYXYB or our product candidates, if approved; 

•the status and cost of our marketing commitments for ZTlido, GLOPERBA, ELYXYB and our product candidates; 

•announcements regarding results of any clinical trials relating to our product candidates; 

•unanticipated serious safety concerns related to the use of ZTlido, GLOPERBA, ELYXYB or any of our product candidates; 

•adverse regulatory decisions; 

•changes in laws or regulations applicable to ZTlido, GLOPERBA, ELYXYB or our product candidates, including but not limited to clinical trial requirements for approvals; 

•legal disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for ZTlido, GLOPERBA, ELYXYB or our product candidates, government investigations and the results of any proceedings or lawsuits, including, but not limited to, patent or stockholder litigation; 

•our decision to initiate a clinical trial, not initiate a clinical trial or to terminate an existing clinical trial; 

•our dependence on third parties; 

•announcements of the introduction of new products by our competitors; 

•market conditions and trends in the pharmaceutical and biotechnology sectors; 

•announcements concerning product development results or intellectual property rights of others; 

•future issuances of common stock or other securities; 

•the recruitment or departure of key personnel; 

•failure to meet or exceed any financial guidance or expectations regarding product development milestones that we may provide to the public; 

•actual or anticipated variations in quarterly operating results; 

•our failure to meet or exceed the estimates and projections of the investment community; 

•overall performance of the equity markets and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in